Simcere Pharmaceutical Group Ltd (S2P) – aksjekurser og nyheter

Symboler Symboler	Pris	Endring	Endring (%)	Trend	Forrige pris ved stengetid	Åpne	Høy	Lav	Volum	Markedsverdi
SIXB Materials SIXB Materials	SIXB −0,77%	1 093,68	−8,50	−0,77%	—	1 102,18	1 096,24	1 103,05	1 092,86	—	—
SIXC Communications SIXC Communications	SIXC −0,88%	610,79	−5,45	−0,88%	—	616,24	616,24	617,68	610,92	—	—
SIXE Energy SIXE Energy	SIXE +0,92%	1 200,68	+10,96	+0,92%	—	1 189,72	1 194,74	1 202,79	1 188,58	—	—
SIXI Industrials SIXI Industrials	SIXI +0,92%	1 741,57	+15,88	+0,92%	—	1 725,69	1 730,02	1 762,99	1 730,02	—	—
SIXM Financials SIXM Financials	SIXM −1,49%	634,06	−9,56	−1,49%	—	643,62	643,13	643,17	634,29	—	—
SIXR Staples SIXR Staples	SIXR +1,51%	842,36	+12,57	+1,51%	—	829,79	832,32	843,23	832,32	—	—
SIXRE Real estate SIXRE Real estate	SIXRE +0,25%	213,94	+0,54	+0,25%	—	213,40	213,40	216,05	213,40	—	—
SIXT Technology SIXT Technology	SIXT −2,12%	3 118,31	−67,61	−2,12%	—	3 185,92	3 160,89	3 178,72	3 120,03	—	—
SIXU Utilities SIXU Utilities	SIXU +2,29%	929,76	+20,82	+2,29%	—	908,94	912,57	932,57	912,57	—	—
SIXV Health care SIXV Health care	SIXV −0,72%	1 468,38	−10,58	−0,72%	—	1 478,96	1 478,17	1 482,91	1 468,74	—	—
SIXY Discretionary SIXY Discretionary	SIXY −1,57%	2 367,58	−37,78	−1,57%	—	2 405,36	2 390,34	2 402,53	2 367,23	—	—

S2P:FRA

Simcere Pharmaceutical Group Ltd

1,31 €

−1,50%

(−0,020) 1 D

23. apr., 09:07:15 GMT+2 · EUR

Alle symboler

1 D

5 D

1 M

6 M

I år

1 Å

5 Å

MAKS

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for S2P …

Åpne

1,31 €

Høy

1,31 €

Lav

1,31 €

Markedsverdi

32,65 mrd.

Snittvolum

400,00

Volum

0,00

52 u høy

1,60 €

52 u lav

0,94 €

Antall ansatte

Nyhetssaker

Fra kilder på nettet

TipRanks

for 1 døgn siden

Simcere Withdraws and Plans to Resubmit NDA for Atopic Dermatitis Drug Rademikibart

Profil

Simcere Pharmaceutical Group or Simcere Pharmaceutical is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. Its focus is to introduce generic and pharmaceutical products for the treatment of diseases with high incidence and/or mortality rate. The company has introduced a generic anti-stroke medication under the brand name, Bicun, and an anti-cancer medication under the brand name, Endu. Its products include antibiotics, anti-stroke medications, anti-inflammatory drugs, anti-cancer medications and other medicines. In addition, it has obtained approvals from the China State Food and Drug Administration to manufacture and sell over 210 other products. Wikipedia

Om Simcere Pharmaceutical Group Ltd

Administrerende direktørRen Jinsheng

Ansatte7,04k

Grunnlagt1995

HovedkontorNanjing, Jiangsu, Kina

Sektor-

Nettstedsimcere.com

Alle verdier i CNY	mars 2025	juni 2025	sep. 2025	des. 2025
Inntekt	1,79 mrd.	1,79 mrd.	2,07 mrd.	2,07 mrd.
Varekostnad	345,53 mill.	345,53 mill.	365,25 mill.	365,25 mill.
Direkte driftskostnader	345,53 mill.	345,53 mill.	365,25 mill.	365,25 mill.
Utgifter til forskning og utvikling	316,21 mill.	316,21 mill.	465,30 mill.	465,30 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	807,37 mill.	807,37 mill.	949,52 mill.	949,52 mill.
Driftskostnader	1,09 mrd.	1,09 mrd.	1,36 mrd.	1,36 mrd.
Totale driftskostnader	1,44 mrd.	1,44 mrd.	1,72 mrd.	1,72 mrd.
Driftsinntekter	357,23 mill.	357,23 mill.	351,33 mill.	351,33 mill.
Andre ikke-operasjonelle inntekter	-	-	-	-
EBT inkludert uvanlige elementer	331,24 mill.	331,24 mill.	425,92 mill.	425,92 mill.
EBT uten uvanlige elementer	350,09 mill.	350,09 mill.	348,89 mill.	348,89 mill.
Kostnad for inntektsskatt	29,44 mill.	29,44 mill.	55,72 mill.	55,72 mill.
Faktisk avgiftssats	8,89 %	8,89 %	13,08 %	13,08 %
Andre driftskostnader	−34,30 mill.	−34,30 mill.	−56,27 mill.	−56,27 mill.
Nettoinntekt	301,80 mill.	301,80 mill.	370,20 mill.	370,20 mill.
Netto fortjenestemargin	16,84 %	16,84 %	17,86 %	17,86 %
Resultat per aksje	-	-	-	-
Rente- og investeringsinntekter	13,27 mill.	13,27 mill.	14,60 mill.	14,60 mill.
Rentekostnader	−24,27 mill.	−24,27 mill.	−23,63 mill.	−23,63 mill.
Netto rentekostnader	−10,99 mill.	−10,99 mill.	−9,03 mill.	−9,03 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	409,84 mill.	409,84 mill.	403,94 mill.	407,12 mill.
Gevinst eller tap ved salg av eiendeler	-	-	-	-

AI-innhold kan inneholde feil. Finn ut mer

HjelpSend tilbakemeldingPersonvern Vilkår Ansvarsfraskrivelse

Finance

Utforskning